SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, released today new data presented at the Options for Control of Influenza (OPTIONS XI) conference, which is hosted by the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) in Belfast, Northern Ireland, from Sept. 26-29, showing its fully-human polyclonal antibody platform maintains its efficacy against multiple variants of several highly mutating viruses.
On Thursday, Sept. 29, at 11:24 am BST, SAB will deliver an oral presentation of its Phase 2a challenge trial that shows SAB-176 reduced the viral load in subjects exposed to H1N1 influenza virus, improved symptoms by day four and shortened the timeframe for viral shedding. On Tuesday, Sept. 27, SAB conducted a poster presentation highlighting data that its SAB-185 COVID-19 polyclonal antibody therapeutic candidate was effective in animal models against the majority of known SARS-CoV2 variants, including the recently evolving Omicron variants.
https://finance.yahoo.com/news/sab-biotherapeutics-unveils-data-isirv-120000050.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.